Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.
作者信息
Dummer Reinhard, Gyorki David E, Hyngstrom John R, Ning Meng, Lawrence Tatiana, Ross Merrick I
机构信息
University Hospital of Zurich, Zurich, Switzerland.
Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Australia.
出版信息
JAMA Oncol. 2023 Oct 1;9(10):1457-1459. doi: 10.1001/jamaoncol.2023.2789.
Abstract
摘要
相似文献
1
Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.评估晚期黑色素瘤新辅助使用替利莫吉欧·拉赫帕里韦克联合手术的5年最终随访结果：一项随机临床试验
JAMA Oncol. 2023 Oct 1;9(10):1457-1459. doi: 10.1001/jamaoncol.2023.2789.
2
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.替莫唑胺联合替莫唑胺胶束用于治疗恶性胶质瘤的疗效观察
Cancer Immunol Immunother. 2020 May;69(5):759-769. doi: 10.1007/s00262-020-02487-x. Epub 2020 Feb 12.
3
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
4
Neoadjuvant Talimogene Laherparepvec for the Treatment of Metastatic Melanoma.用于治疗转移性黑色素瘤的新辅助talimogene laherparepvec
Am Surg. 2017 Jul 1;83(7):e266-268.
5
Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.一名95岁患者的转移性黑色素瘤对talimogene laherparepvec治疗有效，随后接受纳武单抗治疗。
Acta Oncol. 2017 Oct;56(10):1327-1330. doi: 10.1080/0284186X.2017.1324212. Epub 2017 May 8.
6
Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.塔利莫吉拉帕里韦综述：晚期黑色素瘤的首个溶瘤病毒类肿瘤治疗药物
J Am Acad Dermatol. 2020 Jul;83(1):189-196. doi: 10.1016/j.jaad.2020.01.039. Epub 2020 Jan 28.
7
How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.我们如何开展治疗：注射用重组人5型腺病毒（Talimogene Laherparepvec，T-VEC）瘤内免疫疗法治疗晚期黑色素瘤的管理指南
Dermatol Surg. 2020 Nov;46(11):1455-1457. doi: 10.1097/DSS.0000000000002098.
8
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.新辅助替莫唑胺联合手术对比单纯手术治疗可切除 IIIB-IVM1a 期黑色素瘤的随机、开放标签、Ⅱ期临床试验
Nat Med. 2021 Oct;27(10):1789-1796. doi: 10.1038/s41591-021-01510-7. Epub 2021 Oct 4.
9
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.替莫唑胺胶囊用于治疗脑胶质瘤的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):469-473. doi: 10.1080/17425255.2018.1455825. Epub 2018 Mar 23.
10
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.替莫唑胺在非注射病灶中上调免疫细胞群体：来自 IIIB-IVM1c 期黑色素瘤患者的 II 期、多中心、开放性研究的结果。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001621.
引用本文的文献
1
Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge.黑色素瘤皮肤癌：当前知识的全面综述
Cancers (Basel). 2025 Sep 5;17(17):2920. doi: 10.3390/cancers17172920.
2
Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review.溶瘤病毒疗法在黑色素瘤治疗中的进展：全面综述
Vaccines (Basel). 2025 Jul 3;13(7):727. doi: 10.3390/vaccines13070727.
3
The Role of Neoadjuvant Immunotherapy in the Management of High-Risk Stage III Resectable Melanoma: A Literature Review.新辅助免疫疗法在高危Ⅲ期可切除黑色素瘤治疗中的作用：文献综述
Cancers (Basel). 2025 Jun 26;17(13):2152. doi: 10.3390/cancers17132152.
4
Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.溶瘤病毒治疗中晚期实体瘤的疗效：一项系统评价和荟萃分析。
J Virol. 2025 Jul 22;99(7):e0064025. doi: 10.1128/jvi.00640-25. Epub 2025 Jun 20.
5
Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer.靶向TBK1通过增强ICAM1介导的化疗耐药性结直肠癌中的自然杀伤细胞免疫来增强溶瘤病毒疗法。
J Immunother Cancer. 2025 Jun 8;13(6):e011455. doi: 10.1136/jitc-2024-011455.
6
Advanced progress in the genetic modification of the oncolytic HSV-1 virus.溶瘤性单纯疱疹病毒1型（HSV-1）基因改造的前沿进展。
Front Oncol. 2025 Jan 21;14:1525940. doi: 10.3389/fonc.2024.1525940. eCollection 2024.
7
In Search of the Shot to Kill Cancer: Possibilities and Limitations.寻找攻克癌症的良方：可能性与局限性
Ann Surg Oncol. 2025 Mar;32(3):1391-1393. doi: 10.1245/s10434-024-16785-6. Epub 2024 Dec 24.
8
Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.通过瘤内免疫疗法对肿瘤-淋巴管串扰进行治疗性免疫调节
Mol Pharm. 2024 Dec 2;21(12):5929-5943. doi: 10.1021/acs.molpharmaceut.4c00692. Epub 2024 Oct 31.
9
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.与接受talimogene laherparapvec治疗的黑色素瘤患者临床反应相关的遗传因素：一项单机构回顾性分析
Ann Surg Oncol. 2025 Jan;32(1):482-494. doi: 10.1245/s10434-024-16346-x. Epub 2024 Oct 18.
10
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?在黑色素瘤和非黑色素瘤皮肤恶性肿瘤中，溶瘤病毒目前处于什么阶段？
Pharmaceuticals (Basel). 2024 Jul 9;17(7):916. doi: 10.3390/ph17070916.
Zotero 插件